https://www.selleckchem.com/products/ad-5584.html
Exosomes are recognized as promising biomarkers for early cancer diagnosis and prognosis owing to a large amount of biological information they carried. But the key is that single type of exosomal biomarker analysis is not sufficient enough for accurate cancer diagnosis and stage monitoring due to the insufficient information and high false positive signal. To address the challenge, here simultaneous in situ detection of different types of exosomal biomarkers (surface proteins CD81, ephrin type-A receptor 2, and carbohydrate antigen 19-
Like
Comment
Share
